Pancreaticoduodenectomy in Elderly Pancreatic Ductal Adenocarcinoma Patients
Long-term Benefit of Elderly Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy
1 other identifier
observational
5,910
0 countries
N/A
Brief Summary
We used the SEER database to analyze the data of patients with PDAC. The database includes patients of 18 registries in the USA from 1973-2013All the malignant cases were followed-up annually to determine vital status. The aim of Our study is to make clearly the long-term survival of younger (age \<80 years) and elderly (age ≥80 years) pancreatic cancer patients underwent PD. Sec-ond, find out the risk factors of poor prognosis in elderly patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2004
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 13, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2018
CompletedFirst Submitted
Initial submission to the registry
September 4, 2018
CompletedFirst Posted
Study publicly available on registry
September 6, 2018
CompletedSeptember 6, 2018
September 1, 2018
10 years
September 4, 2018
September 4, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
median OS
The median overall survival of all patients
to 2013 Dec. 31
Study Arms (2)
younger patients (age < 80)
age \< 80 patients， All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
older patients (age≥ 80 )
age ≥ 80 years-old patients，All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
Interventions
pancreaticoduodenectomy
Eligibility Criteria
Pancreatic ductal adenocarcinoma patients in the SEER database form 2003 to 2013.
You may qualify if:
- Patients with pancreatic ductal adenocarcinoma，treatment by pancreaticoduodenectomy.Only cases that underwent PD and microscopically confirmed were included.
You may not qualify if:
- Patients with no survival data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 4, 2018
First Posted
September 6, 2018
Study Start
January 1, 2004
Primary Completion
December 13, 2013
Study Completion
September 1, 2018
Last Updated
September 6, 2018
Record last verified: 2018-09
Data Sharing
- IPD Sharing
- Will not share